Summit Therapeutics Inc. Cash and Restricted Cash
Summit Therapeutics Inc. (SMMT) had Cash and Restricted Cash of $419.68 million as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-23
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $419.68M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $106.83M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $225.58M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $238.88M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $419.68M 10-Q · filed 2026-07-23 |
| 2026-03-31 | $106.83M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $225.58M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $238.88M 10-Q · filed 2025-10-20 |
| 2025-06-30 | $298.19M 10-Q · filed 2026-07-23 |
| 2025-03-31 | $211.84M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $105.19M 10-Q · filed 2026-07-23 |
| 2024-09-30 | $94.10M 10-Q · filed 2025-10-20 |
| 2024-06-30 | $28.75M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $61.61M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $71.42M 10-K · filed 2026-02-23 |
| 2023-09-30 | $23.79M 10-Q · filed 2024-10-30 |
| 2023-06-30 | $42.12M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $70.97M 10-Q · filed 2024-05-01 |
| 2022-12-31 | $648.61M 10-K · filed 2026-02-23 |
| 2022-09-30 | $121.97M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $57.34M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $77.45M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $71.79M 10-K · filed 2025-02-24 |
| 2021-09-30 | $80.25M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $103.39M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $102.19M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $66.42M 10-K · filed 2023-03-09 |
| 2020-09-30 | $21.27M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $36.41M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $54.94M 10-Q · filed 2021-05-17 |
| 2019-12-31 | $63.84M 10-K/A · filed 2022-12-21 |
| 2019-09-30 | $21.64M 10-Q · filed 2020-11-16 |
| 2019-06-30 | $27.21M 8-K · filed 2020-09-29 |
| 2019-01-31 | $35.24M 10-K · filed 2021-03-31 |
| 2018-12-31 | $12.14M 10-Q · filed 2020-11-16 |
| 2018-01-31 | $28.50M 10-K · filed 2021-03-31 |
| 2017-01-31 | $35.32M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |